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Preface
Inthelastnumberofyears,therehasbeenarenewedinterest
in the physiological function of proinsulin C-peptide and the
effects of its substitution on type 1 diabetic complications.
Itwasoriginallybelievedthattheonlybiologicalfunctionof
C-peptide was that of a spacer in the biosynthesis of the insulin
molecule and that it was then cleaved off from insulin without
any further biological effect. However, in recent years, several
physiologicaleffectsofC-peptidehavebeenestablished,whose
perturbationsinC-peptide–deﬁcienttype1diabetesplayimpor-
tant roles in the pathogenesis of several chronic complications,
such as nephropathy, retinopathy, neuropathy, and primary
encephalopathy.
So,forinstance,thereisoverwhelmingevidenceestablishing
the effect of C-peptide on Na+,K+-ATPase and NO activities
in several target tissues and on gene regulatory effects of var-
ious trophic factors and their receptors, including the insulin
receptor. Furthermore, it has modulatory post-translational ef-
fects on adhesive molecules determining protein-protein inter-
actions. Recently, it was also shown that C-peptide has gene
regulatory effects on extracellular matrix proteins and that it
exerts antiapoptotic effects.
Despite the evolving wealth of information regarding its
pathophysiological place in type 1 diabetes, the receptor
through which it exerts its activities remains elusive. Never-
theless, it has been shown that C-peptide binds to cell mem-
branes with high afﬁnity, and that it shares with insulin many
of its signaling characteristics. Limited clinical investigations
seem to conﬁrm much of the experimental data with respect to
the more severe microvascular complications associated with
type1diabetes.TheseincludebeneﬁcialeffectsofC-peptidere-
placementonsomaticandautonomicneuropathy,nephropathy,
retinopathy, and the lately recognized primary encephalopathy.
This special issue of Experimental Diabesity Research
presents a compilation of up-to-date reviews by the leaders in
C-peptide research. I am hopeful that this issue will be a valu-
ablecomprehensiveupdateonC-peptideresearchthatwillben-
eﬁt clinicians and diabetologists caring for the increasing num-
beroftype1patients,aswellasforclinicalandbasicinvestiga-
tors and students with an interest in the research into diabetes
and its devastating complications.
Anders A. F. Sima
Detroit, December, 2003
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